Media Release
- Key Opinion Leaders to discuss data presented at ASH meeting
- Webcast available on December 9
Copenhagen, Denmark; December 3, 2014 – Genmab A/S (OMX: GEN) will webcast its Post-ASH investor seminar focused on the company’s latest developments in antibody innovation on December 9, 2014 from 9:30PM to 11:30PM CET. The seminar will include presentations by key opinion leaders describing data from studies of daratumumab and ofatumumab presented at the 56th Annual Meeting of the American Society of Hematology (ASH). Genmab will also discuss the company’s pre-clinical pipeline, the proprietary DuoBody® and HexaBody™ technologies and will present its 2015 Key Goals.
The following cancer experts and senior Genmab staff will attend the event:
- Professor Antonio Palumbo, M.D., Myeloma Unit, Division of Hematology, University of Torino, Torino, Italy
- Professor Torben Plesner, Department of Hematology, Vejle Hospital, Vejle, Denmark
- Dr. Paul Richardson, Clinical Director, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, RJ Corman Professor of Medicine, Harvard Medical School, Boston MA, USA
- Professor Thomas Valerius, Section for Stem Cell Transplantation and Immunotherapy, University Hospital of Schleswig-Holstein, Kiel, Germany
- Professor Marinus H.J. van Oers, Department of Hematology, Academic Medical Center, Amsterdam, the Netherlands
- Dr. Jan van de Winkel, President and CEO, Genmab
- David Eatwell, Executive Vice President and CFO, Genmab
- Dr. Michael K. Bauer, Ph.D., Senior Vice President, Clinical Development, Genmab
- Dr. Steen Lisby, Senior Medical Director, Genmab
To view the webcast via WebEx, visit: http://cache.merchantcantos.com/webcast/webcaster/4000/7464/16532/43432/Lobby/default.htm. WebEx viewers may submit questions during the Q&A portion of the live webcast via the webcast player or by dialing +44 20 3003 2666 (international participants) or +1 866 966 5335 (US participants). An archive of the webcast will be available on Genmab’s website. The webcast will be conducted in English.
The seminar is taking place at the Grand Hyatt San Francisco, San Francisco.
About Genmab A/S
Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated human antibody therapeutics for the treatment of cancer. Founded in 1999, the company currently has one marketed antibody, Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications and daratumumab in late stage clinical development for multiple myeloma. Additionally Genmab has a clinical pipeline with both late and early stage programs, and an innovative pre-clinical pipeline. Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, and the HexaBody™ platform which creates effector function enhanced antibodies. Genmab's deep antibody expertise is expected to provide a stream of future product candidates. Partnering of selected innovative product candidates and technologies is a key focus of Genmab’s strategy and the company has alliances with top tier pharmaceutical and biotechnology companies. For more information visit www.genmab.com.
Contact:
Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communication
T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com
This Media Release contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com. Genmab does not undertake any obligation to update or revise forward looking statements in this Media Release nor to confirm such statements in relation to actual results, unless required by law.
Genmab A/S and its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo™; the DuoBody logo™; the HexaBody logo™; HuMax®; HuMax-CD20®; DuoBody®; HexaBody™ and UniBody®. Arzerra® is a registered trademark of the GSK group of companies.
Media Release no. 08
CVR no. 2102 3884
Genmab A/S
Bredgade 34E
1260 Copenhagen K
Denmark
